CD8A and glioblastoma: To evaluate whether proteasomal degradationinfluences T cell priming in clinical settings, we used the modelto evaluate degron activity across three clinical trial studies ofpersonalized vaccine peptides: two for melanoma56,57 and one for glioblastoma.58 We evaluatedthe immunizing peptide sequences from these studies by dividing theresults into two separate groups: presence (+) or absence (−)of CD8+ T cell responses after vaccination.